Abstract:Immunization of the world population before an influenza pandemic such as the 2009 H1N1 virus spreads globally is not possible with current vaccine production platforms. New influenza vaccine technologies, such as virus-like-particles (VLPs), offer a promising alternative. Here, we tested the immunogenicity and protective efficacy of a VLP vaccine containing hemagglutinin (HA) and M1 from the 2009 pandemic H1N1 influenza virus (H1N1pdm) in ferrets and compared intramuscular (i.m.) and intranasal (i.n.) routes of immunization. Vaccination of ferrets with VLPs containing the M1 and HA proteins from A/California/04/2009 (H1N1pdm) induced high antibody titers and conferred significant protection against virus challenge. VLP-vaccinated animals lost less weight, shed less virus in nasal washes, and had markedly lower virus titers in all organs tested than naïve controls. A single dose of VLPs, either i.m. or i.n., induced higher levels of antibody than did two doses of commercial split vaccine. Ferrets vaccinated with split vaccine were incompletely protected against challenge; these animals had lower virus titers in olfactory bulbs, tonsils, and intestines, but lost weight and shed virus in nasal washes to a similar extent as naïve controls. Challenge with heterologous A/Brisbane/59/07 (H1N1) virus revealed that the VLPs conferred minimal cross-protection to heterologous infection, as revealed by the lack of reduction in nasal wash and lung virus titers and slightly higher weight loss relative to controls. In summary, these experiments demonstrate the strong immunogenicity and protective efficacy of VLPs compared to the split vaccine and show that i.n. vaccination with VLPs has the potential for highly efficacious vaccination against influenza.

Protection Induced by Early Stage Vaccination with Pandemic Influenza Virus-Like Particles.

A Pandemic H1N1 Influenza Virus-Like Particle Vaccine Induces Cross-Protection in Mice

Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles

Virus-Like Particle Vaccine Induces Protective Immunity Against Homologous and Heterologous Strains of Influenza Virus

Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins

Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection Against 2009 H1N1 Pandemic Influenza

Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from That Induced by Split Influenza Virus

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Immunization with a Low Dose of Hemagglutinin-Encoding Plasmid Protects Against 2009 H1N1 Pandemic Influenza Virus in Mice.

Intramuscular and Intranasal Immunization with an H7N9 Influenza Virus-Like Particle Vaccine Protects Mice Against Lethal Influenza Virus Challenge.

Virus-like Particle Vaccine Comprised of the HA, NA, and M1 Proteins of an Avian Isolated H5N1 Influenza Virus Induces Protective Immunity Against Homologous and Heterologous Strains in Mice.

Preliminary Study on H1N1 Virus-Like Particle Vaccine

Kinetics of Immune Responses to Influenza Virus-Like Particles and Dose-Dependence of Protection with A Single Vaccination

Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus

Influenza vaccines based on virus-like particles.

Sequential Immunizations with Heterosubtypic Virus-Like Particles Elicit Cross Protection Against Divergent Influenza A Viruses in Mice

Influenza M1 VLPs Containing Neuraminidase Induce Heterosubtypic Cross-Protection.

Induction of protective immune response to intranasal administration of influenza virus‐like particles in a mouse model

Incorporation of Conserved Nucleoprotein into Influenza Virus-Like Particles Could Provoke a Broad Protective Immune Response in BALB/c Mice and Chickens

Baculovirus-derived influenza virus-like particle confers complete protection against lethal H7N9 avian influenza virus challenge in chickens and mice

A Bivalent Influenza VLP Vaccine Confers Complete Inhibition of Virus Replication in Lungs.